A Potential Drug Target and Biomarker: YOD1 (DKFZp451J1719) (G55432)

Target Name: YOD1

NCBI ID: G55432

YOD1

A Potential Drug Target and Biomarker: YOD1 (DKFZp451J1719)

YOD1 (DKFZp451J1719), a gene encoding for a protein named YOD1, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure, location, and function make it an attractive target for the development of new therapeutics. In this article, we will explore the biology of YOD1, its potential drug targets, and its potential as a biomarker for disease.

Background

YOD1 is a gene located on chromosome 1719 of the human genome, which encodes a protein with 254 amino acid residues. The protein has a unique structure, with a 21 amino acid extension at its C-terminus, which is not found in any other protein. This extension is known as the \"YOD1-specific extension\" or \"YOD1-unique region.\" The YOD1 protein is expressed in various tissues and cells of the body and has been implicated in various physiological processes, including cell signaling, inflammation, and stress responses.

Potential Drug Targets

YOD1 has been identified as a potential drug target due to its unique structure and function. The YOD1 protein is involved in various signaling pathways, including the TGF-β pathway, which plays a crucial role in cell signaling and growth. The TGF-β pathway is a well-established target for many drugs, including anti-cancer agents, and YOD1 has been shown to be involved in the regulation of TGF-β signaling in various cell types.

In addition to its involvement in TGF-β signaling, YOD1 has also been shown to play a role in cell adhesion and migration. YOD1 has been shown to be involved in the regulation of cell-cell adhesion in various tissues, including neural and epithelial cells. Furthermore, YOD1 has been shown to be involved in the regulation of cell migration in various cell types, including cancer cells.

Potential Biomarkers

YOD1 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. due to its unique structure and function, YOD1 has been shown to be involved in the regulation of various biological processes, including cell signaling, inflammation, and stress responses.

In cancer, YOD1 has been shown to be involved in the regulation of cell signaling, including the TGF-β pathway. The TGF-β pathway is a well-established target for many anti-cancer drugs, including monoclonal antibodies, tyrosine kinase inhibitors, and angiogenesis inhibitors. Therefore, YOD1 may be an attractive target for the development of new anti-cancer drugs.

In neurodegenerative disorders, YOD1 has been shown to be involved in the regulation of cell signaling and stress responses. The TGF-β pathway is involved in the regulation of stress responses in neurons, and YOD1 has been shown to be involved in the regulation of TGF-β signaling in these cells. Therefore, YOD1 may be an attractive target for the development of new neurodegenerative disorder therapies.

In autoimmune diseases, YOD1 has been shown to be involved in the regulation of cell signaling and inflammation. The TGF-β pathway is involved in the regulation of inflammation in these diseases, and YOD1 has been shown to be involved in the regulation of TGF-β signaling in these cells. Therefore, YOD1 may be an attractive target for the development of new autoimmune disease therapies.

Conclusion

In conclusion, YOD1 is a gene encoding for a protein with unique structure and function that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its involvement in various signaling pathways and its unique location on

Protein Name: YOD1 Deubiquitinase

Functions: Hydrolase that can remove conjugated ubiquitin from proteins and participates in endoplasmic reticulum-associated degradation (ERAD) for misfolded lumenal proteins. May act by triming the ubiquitin chain on the associated substrate to facilitate their threading through the VCP/p97 pore. Ubiquitin moieties on substrates may present a steric impediment to the threading process when the substrate is transferred to the VCP pore and threaded through VCP's axial channel. Mediates deubiquitination of 'Lys-27'-, 'Lys-29'- and 'Lys-33'-linked polyubiquitin chains. Also able to hydrolyze 'Lys-11'-linked ubiquitin chains. Cleaves both polyubiquitin and di-ubiquitin. May play a role in macroautophagy, regulating for instance the clearance of damaged lysosomes. May recruit PLAA, UBXN6 and VCP to damaged lysosome membranes decorated with K48-linked ubiquitin chains and remove these chains allowing autophagosome formation (PubMed:27753622)

The "YOD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about YOD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets